Search results
Results from the WOW.Com Content Network
Lisdexamfetamine was approved for medical use in the United States in 2007, and in the European Union in 2012. [16] [21] In 2022, it was the 69th most commonly prescribed medication in the United States, with more than 9 million prescriptions.
The number of new psychiatric drugs, and especially antidepressants on the market in Japan, is significantly less than Western countries. [1]One of the biggest barriers to antidepressants coming to the market is that the medical insurance system in Japan is national, and the authorities are keen to contain a potentially explosive market for drugs like antidepressants that, from the Japanese ...
Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo; Viibryd – an antidepressant of the serotonin modulator and stimulators class; Vivactil (protriptyline) an antidepressant also used in the treatment of nerve pain
The Drug Enforcement Administration is increasing the production limit of Vyvanse and its generic equivalents by about 24% to address the ongoing global shortage of ADHD medications.
(Reuters) -The U.S. Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing ...
Illegal drug trafficking cases increased by 10 percent to 326 in 2011 compared with 2010. About 509 kilograms of stimulants and cannabis powder drugs were seized, up 40 per cent on the previous year. Seizures of 20,000 MDMA, psychotropic drugs and other tablets were down 40 per cent from last year.
Millions of children and adults in the United States are prescribed medications to treat ADHD, a neurological disorder which causes differences in the brain that affect executive functioning.
Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019. Shire was a global biotechnology company focused on serving people with rare diseases and other highly specialized conditions.